Short answer
ImmunityBio, Inc. (IBRX) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $51M (up 93.9% year over year) with net income of −$230M.
Q2 2026 key financials · XBRL
- Revenue
- $51M
- +93.9% YoY · +15.9% QoQ
- Net income
- −$230M
- −148.9% YoY · +63.6% QoQ
- Operating margin
- -120.4%
- EPS (diluted)
- −$0.21
- −90.9% YoY · +66.1% QoQ
Source: XBRL data from the ImmunityBio, Inc. (IBRX) Q2 2026 10-Q on SEC EDGAR. USD.
ImmunityBio, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Accumulated deficit $4.6 billion as of June 30, 2026, with continued losses expected
- Additional financing need, with cash, equivalents, and marketable securities totaling $357.4 million
- $480.0 million related-party convertible promissory note held by an entity affiliated with Dr. Soon-Shiong
- ANKTIVA demand exposed to TICE BCG shortages, the only FDA-approved U.S. BCG strain
- Third-party failures involving cGMP manufacturing or GCP trials could delay approvals or trigger regulatory sanctions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ImmunityBio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.